An sveir model for assessing potential impact of an imperfect anti-SARS vaccine

Mathematical Biosciences and Engineering

Volumn 3, Issue 3, 2006, Pages 485-512

  Gumel, A B ^a   Connell Mccluskey, C ^b   Watmough, James ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b WILFRID LAURIER UNIVERSITY   (Canada)

^c UNIVERSITY OF NEW BRUNSWICK   (Canada)

Author keywords

Control reproduction number; Disease transmission model; Epidemiology; Severe acute respiratory syndrome (SARS); Vaccination

Indexed keywords

EID: 33846963792     PISSN: 15471063     EISSN: 15510018     Source Type: Journal    
DOI: 10.3934/mbe.2006.3.485     Document Type: Article

References (53)

1. Alexander, M. E., Bowman, C., Moghadas, S. M., Summers, R., Gumel, A. B. and Sahai, B. M. (2004). A vaccination model for transmission dynamics of influenza. SIAM J. Appl. Dyn. Syst. 3(4): 503-524.
2. Anderson, R. M. and May, R. M. (1991). Infectious Diseases of Humans, Oxford Univ. Press, London.
3. Anderson, R. M. and Garnett, G. P. (1996). Low-efficacy HIV vaccines: potential for community-based intervention programmes. Lancet 348: 1010-1013.
4. Arino, J., McCluskey, C. C., van den Driessche, P. (2003). Global results for an epidemic model with vaccination that exhibits backward bifurcation. SIAM J. Appl. Math. 64(1): 260-276
5. Blower, S. M. and Dowlatabadi, H. (1994). Sensitivity and uncertainty analysis of complex models of disease transmission: and HIV Model, as an example. International Statistical Review 62(2): 229-243.
6. Blower, S. M. and A. McLean (1994). Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science 265: 1451-1454.
7. Booth, C. M. (and 20 others) (2003). Clinical features and short-term outcomes of 144 patients with SARS in the Greater Toronto area. JAMA 289: 1-9.
8. Brauer, F. and Castillo-Chavez, C. (2000). Mathematical Models in Population Biology and Epidemiology. Texts in Applied Mathematics Series, Volume 40, Springer-Verlag, New York.
9. 0 and its role on global stability. Mathematical Approaches for Emerging and Reemerging Infectious Diseases: An Introduction. The IMA Volumes in Mathematics and its Applications. Volume 125, pp. 229-250, Springer, New York. Castillo-Chavez, C. with S. Blower, P. van den Driessche, D. Kirschner and A.-A. Yakubu (Eds.)
10. China in SARS vaccine trial. The Scientist, January 12, 2004. http://www.biomedcentral.com/news/20040121/03
11. Chowell, G., Fenimore, P. W., Castillo-Garsow, M.A. and Castillo-Chavez, C. (2003). SARS outbreaks in Ontario, Hong Kong and Singapore: the role of diagnosis and isolation as a control mechanism. J. Theoret. Biol. 224: 1-8.
12. Diekmann, O. and Heesterbeek, J. A. P. (2000). Mathematical Epidemiology of Infectious Diseases: Model Building, Analysis and Interpretation, Wiley, New York.
13. Dowell, S. F. and Ho, M. S. (2004). Seasonality of infectious diseaseand severe acute respiratory syndrome - what we don't know can hurt us, Lancet Infect Dis 4: 704-08
14. Drosten, C. (and 24 others) (2003). Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348: 1967-1976.
15. Dwosh, H. A., Hong, H. H., Austgarden, D., Herman, S. and Schabas, R. (2003). Identification and containment of an outbreak of SARS in a community hospital. CMAJ 168: 1415-1420.
16. Elbasha, E. H. and Gumel, A. B. Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits. Bulletin of Mathematical Biology. To appear.
17. Gandon, S., Mackinnon, M., Nee, S. and Read, A. (2003). Imperfect vaccination: some epidemiological and evolutionary consequences. Proc. Roy. Soc. Lond., Series B 270: 1129-1136.
18. Glass, K. and Grenfell, B. (2003). Antibody dynamics in childhood diseases: waning and boosting of immunity and the impact of vaccination. J. Theoret. Biol. 221(1): 121-131.
19. Gumel, A. B., S. Ruan, T. Day, J. Watmough, F. Brauer, P. van den Driessche, D. Gabrielson, C. Bowman, M. E. Alexander, S. Ardal, J. Wu and B. M. Sahai (2004). Modeling strategies for controlling SARS outbreaks based on Toronto, Hong Kong, Singapore and Beijing experience. Proc. Roy. Soc. Lond., Series B 271: 2223-2232.
20. Gumel, A. B., Moghadas, S. M. and Mickens, R. E. (2004). Effect of a preventive vaccine on the dynamics of HIV transmission. Commun. Nonlinear Sci. Numer. Simul. 9: 649-659.
21. Hale, J. K. (1969). Ordinary differential equations, John Wiley & Sons, New York
22. Hethcote, H. W. (1989). Three basic epidemiological models, in Levin, S.A., Hallam, T.G. & Gross, L.J (eds) Applied Mathematical Ecology, Springer-Verlag, Berlin, pp. 119-144
23. Hethcote, H. W. (2000). The mathematics of infectious diseases. SIAM Review 42: 599-653.
24. Hethcote, H. W. (2001). New vaccination strategies for pertussis. Mathematical Approaches for Emerging and Reemerging Infectious Diseases: An Introduction. IMA Series on Mathematics and Its Applications, Springer, New York, 25: 97-118. C. Castillo-Chavez, S. Blower, P. van den Driessche, and D. Kirschner (eds.).
25. Hethcote, H. W., Horby, P. and McIntyre, P. (2004). Using computer simulations to compare pertussis vaccination strategies in Australia. Vaccine 22: 2181-2191.
26. Kribs-Zaleta, C. and Velasco-Hernandez, J. (2000). A simple vaccination model with multiple endemic states. Math. Biosci. 164: 183-201.
27. Ksiazek, T. G. (and 25 others) (2003). A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348: 1953-1966.
28. Li, M. Y. and Muldowney, J. S. (1995). On R. A. Smith's autonomous convergence theorem. Rocky Mount. J. Math. 25: 365-379.
29. Li, M. Y. and Muldowney, J. S. (1996). Phase Asymptotic Semiflows, Poincare's Condition and the Existence of Stable Limit Cycles. J. Diff. Eg. 124: 425-448.
30. Lingappa, J. R., McDonald, L. C., Simone, P. and Parashar, U. D. (2004). Wresting SARS from uncertainty. Emerging Infectious Diseases 10 No.2: 167-170.
31. Lipsitch, M. (and 11 others) (2003). Transmission dynamics and control of severe acute respiratory syndrome. Science 300: 1966-1970.
32. Lloyd-Smith, J. O., Galvani, A. P. and Getz, W. M. (2003). Curtailing transmission of severe acute respiratory syndrome within a community and its hospital, Proc. Royal Soc. London Series B, 270: 1979-1989.
33. Marra, M. A. (and 57 others) (2003). The genome sequence of the SARS-associated coronavirus. Science 300: 1399-1404.
34. Martin Jr., R. H. (1974). Logarithmic norms and projections applied to linear differential systems. J. Math. Anal. Appl., 45: 432-454.
35. Massad, E., F. Coutinho, M. Burattini, L. Lopez, and C. J. Struchiner (2001). Modeling the impact of imperfect HIV vaccines on the incidence of the infection. Math. Comput. Modelling 34: 345-351.
36. McCluskey, C. C.. A strategy for constructing Lyapunov functions for non-autonomous linear differential equations. Linear Algebra and its Applications (to appear).
37. McLean, A. and Blower, S. (1993). Imperfect vaccines and herd immunity to HIV. Proc. Roy. Soc. Land. B 253: 9-13.
38. Muldowney, J. S. (1990). Compound matrices and ordinary differential equations. Rocky Mountain J. Math., 20: 857-872.
39. Pang, H., Liu, Y., Han, X., Xu., Y, Jiang, F., Wu, D., Kong, X., Bartlam, M. and Rao, Z. (2004). Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J Gen Virol. 85: 3109-13.
40. Plotkin, S. A. and Orenstein, W. A. (eds) (1999). Vaccines, 3rd edn., Philadelphia, PA: W. B. Saunders.
41. Poutanen, S. M. (and 19 others) (2003). Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 348: 1995-2005.
42. Riley, S. (and 19 others) (2003). Transmission dynamics of etiological agent of SARS in Hong Kong: the impact of public health interventions. Science 300: 1961-1966.
43. Rota, P. A. (and 34 others) (2003). Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300: 1394-1399.
44. Sinovac Biotech Co. (2004). Sinotoc biotech ltd. has received a further US $1.2 million in government research funding for SARS vaccine. See www.sinovac.com/en/content.asp?ID=231.
45. Tamburri, R. (2004). SARS vaccine undergoing animal testing. CMAJ 171(4): 320.
46. Tsang, K. W. (and 15 others) (2003). A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl J. Med. 348: 1977-1985.
47. van den Driessche, P. and Watmough, J. (2002). Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math. Biosci. 180: 29-48.
48. Wang, W. and Ruan, S. (2003). Simulating the SARS outbreak in Beijing with limited data. J. Theoret. Biol. 227: 369-379.
49. Webb, G. F., Blaser, M. J., Zhu, H., Ardal, S. and Wu, J. (2004). Critical role of nosocomial transmission in the Toronto SARS outbreak. Mathematical Biosciences and Engineering. 1(1): 1-13.
50. WHO (2003a). Cumulative number of reported probable cases of SARS. See www.who.int/csr/sars/country/en.
51. WHO (2003b). Case definitions for surveillance of severe acute respiratory syndrome (SARS). See www.who.int/csr/sars/casedefinition/en.
52. Xiong, S. (and 13 others) (2004). Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett. 95(2): 139-143.
53. Yang, Z., W. Kong, Y. Huang, A. Roberts, B. R. Murphy, K. Subbarao and G. J. Nabel (2004). A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428: 561-564.